The parent company of Hybribio, Hong Kong Science & Technology Ltd., established



Co-established Hong Kong Gene Technology Ltd. with the University of Hong Kong, acquired two US patents

– Flow-through Hybridization Technology



Established Chaozhou Hybribio Biological Instrument Ltd. (former name of the company)



Established Chaozhou Hybribio Biochemistry Ltd.



The 1st Hybribio’s HPV Seminar held



Jointly organized with the Ministry of Health and the Chinese Physician Association to conduct trainings for 600 national base-level doctors for 3 years

Assisted Chaozhou government with the cervical cancer screening for 300,000 women in the rural area

Awarded the Social Responsibility Award by the Chinese Physician Association



The Launching Ceremony of China HPV Database System and The 2nd Hybribio’s HPV Seminar held



Guangdong HPV Related Molecular Diagnosis Engineering Technology R&D Center established

Key Program of the 12th Five-Year Plan for the Development of Biomedical Industry in Guangdong Province

HPV health checkup for 120,000 female employees in Daqing Petroleum



Hong Kong Molecular Pathology Diagnostic Centre Ltd. established

The postdoctoral research station established

Key enterprise of strategic emerging industries in Guangdong Province



Hybribio Enterprise Technology Center was named Guangdong Provincial Enterprise Technology Center

HPV cervical cancer screening for 150,000 female civil servants in Hunan Province



Hybribio medical laboratories established nationwide

Guangdong Hybribio Biochip R & D Industrial Base officially established, as a national project for the development of strategic emerging industry

HPV diagnostic kits and the gene chip preparation (ZL200710030723.6) method won the Golden Award of the 2016 Chinese Patent Award



Hybribio (stock code: 300639) was successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market.



Top 50 Biotechnology Innovation Enterprises in the Guangdong, Hong Kong and Macau Greater Bay Area

Hybribio School of Life and Health officially established

Establishment of a workstation for overseas intelligence serving the Country

Formal strategic cooperation with European Molecular Genetic Quality Network (EMQN)



Two COVID-19 diagnostic kits (RT-PCR method and Sanger Sequencing method) developed

Hybribio Medical Laboratories carried out COVID-19 detection all around the country

The first diagnostic kit for detection of 10 reproductive tract infection pathogens simultaneously was approved for selling


Fully devoted to fight against COVID-19 pandemic at home and abroad


Construction commencement of Hybribio Medical Science Park

Monkeypox Virus Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit obtained CE certificate


As of Dec 2023, Hybribio has provided over 1 billion COVID-19 RT-PCR tests in China

Obtained the 1st NMPA approval for cervical cancer primary screening

Pharmacogenetics – ApoE and SLCO1B1 Gene MCA Real-time PCR Kit, MTHFR Gene MCA Real-time PCR Kit obtained NMPA approval


Pharmacogenetics – CYP2C9 and VKORC1 Gene MCA Real-time PCR Kit obtained NMPA approval